Estija - estų - Ravimiamet

bristol-myers squibb - kolestüramiin - suukaudse lahuse pulber - 4g 12tk

Estija - estų - Ravimiamet

bristol-myers squibb pharma eeig - atasanaviir - suukaudne pulber - 50mg 1.5g 180g 1tk

Estija - estų - Ravimiamet

bristol-myers squibb international ltd. - kolestüramiin - suukaudse lahuse pulber - 4g 50tk

Estija - estų - Ravimiamet

bristol-myers squibb company - nivolumab - infusioonilahuse kontsentraat - 10mg 1ml 10ml 5tk

Estija - estų - Ravimiamet

bristol-myers squibb pharmaceuticals s.p.a - lomustiin - kapsel - 10mg 20tk

Estija - estų - Ravimiamet

bristol-myers squibb company - nivolumab - infusioonilahuse kontsentraat - 10mg 1ml 10ml 1tk

Estija - estų - Ravimiamet

bristol-myers squibb eesti as - amfoteritsiin - suukaudne suspensioon - 100mg 1ml 30ml 1tk

Estija - estų - Ravimiamet

bristol-myers squibb gyogyszerkereskedelmi kft. - etoposiid - kapsel - 100mg 10tk

Estija - estų - Ravimiamet

bristol laboratories limited - lisinopriil - tablett - 20mg 28tk

Europos Sąjunga - estų - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastilised ained - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).